Bruker has announced a significant investment in Germany-based company RECIPE Chemicals + Instruments, which provides mass spectrometry-based diagnostic assay kits.
The transaction’s financial aspects remain undisclosed.
Go deeper with GlobalData
The German company offers vendor-agnostic therapeutic drug monitoring (TDM) and in vitro diagnostic kits that are compatible with liquid chromatography-mass spectrometry (LC–MS)/MS, high-performance liquid chromatography (HPLC), and inductively coupled plasma mass spectrometry (ICP-MS) assays.
RECIPE’s managing director Dr Gernot Wolfram spearheads the company’s operations.
Bruker noted that the investment and partnership bolster its offerings in small-molecule clinical diagnostic assays through the integration of ClinMASS kits of RECIPE with Bruker’s EVOQ liquid chromatography triple-quadrupole mass spectrometers and with LC-TQ-MS systems from other manufacturers.
Furthermore, both entities are working to launch chromatography-free (chrom-free) RECIPE ClinDART kits that will operate on the EVOQ-DART TQ systems, allowing transitions between traditional LC-TQ-MS techniques and the high-throughput ClinDART processes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe EVOQ-DART TQ system, in its chrom-free mode, provides throughput for multiplex assays without the need for chromatography while ensuring sensitivity and quantitation through triple-quad mass spectrometry selectivity and multiple-reaction monitoring (MRM) features.
The ClinDART platform enhances sustainability by decreasing solvent consumption by 95%, reducing expenses, and boosting productivity of labs.
It complements RECIPE’s ClinMASS LC-TQ assay offerings and aims to establish new benchmarks for high-throughput TDM, drug screening for abuse, and various other applications.
Bruker Applied Mass Spectrometry senior vice-president Jeffrey Zonderman said: “This majority investment aligns with our strategic vision for LC-TQ-MS assays, enhanced with novel chrom-free assays based on our proprietary DART technology to lead in clinical research and regulated TDM markets.
“The RECIPE ClinMASS and novel ClinDART assays, combined with LC or chrom-free EVOQ DART-TQ methods, are expected to offer unparalleled flexibility, throughput, and cost-effectiveness.”
In June 2024, Bruker launched the neofleX Imaging Profiler MALDI-TOF/TOF for mass spectrometry imaging applications.
